Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 85   

Articles published

SGYP 4.13 +0.15 (3.77%)
price chart
Current Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) PT Means Stock Is Worth ...
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) up 9.94 per cent in the past week, is under coverage of 5 analysts who collectively recommend a buy rating on stock.
Synergy Pharmaceuticals DE (NASDAQ:SGYP) Short Interest Increased By 32.05%  Consumer Eagle
Option Market: Synergy Pharmaceuticals Inc Risk Hits An Unsually High Level
This is a proprietary risk rating for the next 30-days built by Capital Market Laboratories (CMLviz) based on a large number of interactions of data points, many of which come directly from the option market for Synergy Pharmaceuticals Inc (NASDAQ:SGYP) .
Rodman & Renshaw Weighs In on Synergy Pharmaceuticals Inc (SGYP) Ahead of ...
Rodman & Renshaw analyst Ram Selvaraju weighed in today with a few insights on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), ahead of the the upcoming Phase 3 data from Synergy's two pivotal trials of plecanatide in constipation-predominant irritable ...
Company Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) Rally 6.46%  TheFounders Daily
BTIG Analyst Remains Bullish On Synergy Pharmaceuticals Inc (SGYP) Despite NDA ...
Analyst Tim Chiang of BTIG expresses his concern about the slowdown in Synergy Pharmaceuticals Inc's (NASDAQ:SGYP) Phase 3 trials for plecanatide, a treatment for IBS-C, or irritable bowel syndrome with constipation.
BTIG Research Reiterates Buy Rating for Synergy Pharmaceuticals Inc. (SGYP)  Community Financial News
Eye Catching Stock: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)  News Oracle
Synergy Pharmaceuticals Inc. (SGYP) Jumps 5.52% on July 20
Synergy Pharmaceuticals Inc. (SGYP) was among the biggest gainers on the Russell 2000 for Wednesday July 20 as the stock popped 5.52% to $3.82, representing a gain of $0.2 per share.
Canaccord Weighs In on Synergy Pharmaceuticals Inc (SGYP) Following Regulatory ...
In a research report released Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) with a $13.00 price target, after the company announced it has reached the FDA mid-cycle review ...
Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide ...  Business Wire (press release)
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Current Analyst Ratings  Fiscal Standard
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Stock Rises, Analysts: Buy Rating
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) up 10.8 per cent in the past week, is under coverage of 5 analysts who collectively recommend a buy rating on stock.
Synergy Pharmaceuticals (SGYP) Shares are Up 10.8%  TheFounders Daily
New Broker Ratings For Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)  FTSE News
Analyst's Viewpoints: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) , Synergy ...
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) finished the trade at $3.98, higher +0.25%. Its last's traded volume was 1.88 million shares in comparison to its average trading volume of 3.46 million shares.
Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has entered into definitive ...
Synergy Pharmaceuticals (SGYP) Stock: Big Gains Coming Soon  CNA Finance (press release)
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Receives Consensus Recommendation ...
Synergy Pharmaceuticals logo Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has received a consensus recommendation of “Buy” from the eight research firms that are covering the firm.
HC Stocks Outlines: Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Hologic, Inc ...  share market updates (press release)
Synergy Pharmaceuticals (SGYP) : Analyst Rating Update  TheFounders Daily